Endra Life Sciences Raises $8.7 Million In Gross Proceeds Through Its At-The-Market Facility
PUBLIC · NDRAApr 21, 2022
Amount Raised
$8.7 Million
Round Type
Post-IPO Equity
Ann ArborManufacturingBiotechnologyHealth CareMedicalMedical DeviceHealth Diagnostics
Description
ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), announces that the Company has raised $8.7 million in gross proceeds year-to-date from the sale of common stock through its at-the-market (ATM) equity facility. Pursuant to its ATM equity offering sales agreement with Ascendiant Capital Markets LLC, the Company sold approximately 20.6 million shares of common stock at an average price of $0.42 per share.
Company Information
Company
ENDRA Life Sciences
Location
Ann Arbor, Michigan, United States
About
ENDRA Life Sciences is the pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), a ground-breaking technology being developed to visualize tissue like MRI, but at 1/50th the cost and at the point of patient care. TAEUS® is designed to work in concert with 400,000 cart-based ultrasound systems in use globally today. TAEUS® is initially focused on the measurement of fat in the liver as a means to assess and monitor Non-Alcoholic Fatty Liver Disease (NAFLD) and inflammation (NASH), chronic liver conditions that affect over one billion people globally, and for which there are no practical diagnostic tools. Beyond the liver, ENDRA is exploring several other clinical applications of TAEUS®, including visualization of tissue temperature during energy-based surgical procedures. For more information, please visit www.endrainc.com.
Fundz sees it the moment ENDRA Life Sciences raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Ann ArborManufacturingBiotechnologyHealth CareMedicalMedical DeviceHealth Diagnostics